Abstract Library

#2047 IMMUNeOCT Study: The Role of Octreotide LAR in Modulating the Immune Response in Patient with Neuroendocrine Tumors. EudraCT Number 2017-001613-83

Introduction: SSAs are used in the treatment of G1/G2 Neuroendocrine Neoplasms (NEN) in order to control symptoms and induce tumor shrinkage with an excellent tolerability profile. The role of immune response is crucial in defining the clinical response to treatment through the active stimulation of effector cells (T and NK cells) but also through the inhibition of tumor-induced immune suppression. The immune regulatory cells CD4-CD25-expressing Tregs and myeloid cellsMDSC can contribute to disease progression through various mechanisms.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Napolitano M, De Divitiis C, Santagata S, Capozzi M, Ottaiano A,

Keywords: neuroendocrine tumors, somatostatin analogs, immune regulatory cells, Tregs MDSC, Immunotherapy,